Pablo Mozas

33PUBLICATIONS
106CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jul 22, 2026
CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

|Jun 08, 2026
Genomic heterogeneity in primary cutaneous follicular center lymphomas reveals different clinicopathological subgroups.

|Jun 08, 2026
Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

|Oct 16, 2025
Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report.

Daniel Munarriz, Oriana López-Godino, Nuria Martinez-Cibrian

|Sep 15, 2025
Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma.

Núria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego

|Mar 03, 2025
A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis.

Pablo Mozas, Romain Ould Ammar, Loïc Chartier

Pageof 6

Frequent Collaborators

10 joint publications

Ferran Nadeu

9 joint publications

Armando López-Guillermo

9 joint publications

Julio Delgado

8 joint publications

Elías Campo